Milea Timbergen

331 20 . McCarville MB, Hoffer FA, Adelman CS, Khoury JD, Li C, Skapek SX. MRI and biologic behavior of desmoid tumors in children. AJR Am J Roentgenol. 2007;189(3):633-640. 21 . Navid F. NCT04195399 - A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery 2020 Available from: https://clinicaltrials.gov/ct2/show/NCT04195399?term=NCT04195399&draw=2&rank=1. 22 . Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20(9):1263-1272. 23 . Elnekave E. NCT03966742 - Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis 2019 Available from: https://clinicaltrials.gov/ct2/show/NCT03966742?term=NCT03966742&draw=2&rank=1. 24 . Constantinidou A, Jones RL, Scurr M, Al-Muderis O, Judson I. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009;45(17):2930-2934. 25 . Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017;76:60-67. 26 . Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, et al. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer. 2015;51(18):2800-2807. 27 . Libertini M, Mitra I, van der Graaf WTA, Miah AB, Judson I, Jones RL, et al. Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response. Clin Sarcoma Res. 2018;8:13. 28 . Kotecki N, Renaud A, Ben Haj Amor M, Thomassin Defachelles AS, Ryckewaert T, Gamblin V, et al. Is symptom worsening (SW) associated with RECIST response in patients (pts) with desmoid tumors (DT)? Journal of Clinical Oncology. 2016;34((Kotecki N.; Renaud A.; Ben Haj Amor M.; Thomassin Defachelles A.-S.; Ryckewaert T.; Gamblin V.; Robin Y.M.; Taieb S.; Penel N.) Oscar Lambret Center, Lille, France; Centre Oscar Lambret, Lille, France). 29 . Rolstad S, Adler J, Ryden A. Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health. 2011;14(8):1101-1108. 12